Leerink Partners Report Names Carterra a Core Enabler of the $7B "Lab-in-the-Loop" Antibody Discovery Market
核心洞察
Leerink Partners (搜索) estimates a $7 billion total addressable market for life science tools tied to AI-enabled antibody discovery, with $4 billion in the biologics drug discovery layer.
The "Lab-in-the-Loop" paradigm uses AI to propose antibody candidates, wet lab experiments to validate them, and resulting data to refine subsequent AI-driven design cycles.
Carterra (搜索)'s high-throughput surface plasmon resonance (HT-SPR) platforms are identified as critical infrastructure for binding affinity measurement, a core bottleneck in AI-guided discovery.
A new research report from Leerink Partners (搜索) has identified Carterra (搜索) as a core enabling technology in the rapidly expanding market for AI-driven biologics drug discovery, estimating a total addressable market of roughly $7 billion in life science tools demand tied to AI-enabled antibody discovery.
The report, published July 16, 2026, and titled "Lab-in-the-Loop: AI Rewires Antibody Discovery, Unlocking a $7B LST Opportunity," was authored by Leerink Partners (搜索) analyst Puneet Souda and team. It describes "Lab-in-the-Loop" (LitL) as the emerging paradigm in which AI models propose candidate antibody sequences, wet lab experiments test them, and the resulting data feed back to sharpen each subsequent round of design — transforming what was once a slow, serial discovery process into a faster, guided one.
The analysis estimates that the $7 billion total addressable market includes a $4 billion biologics drug discovery layer, of which approximately $1.3 billion is currently outsourced to service providers.
Binding Affinity as the Critical Bottleneck
A central finding of the Leerink report is that the shift toward AI-driven discovery increases rather than diminishes the need for wet lab data. The report singles out binding affinity measurement — the step where gold-standard surface plasmon resonance (SPR) instruments quantify how tightly an antibody binds its target — as a segment that should remain core to the loop rather than merely riding higher project volume.
Leerink's competitive landscape analysis names Carterra (搜索), alongside other technologies, as a primary supplier of this binding affinity infrastructure. As the report describes, AI models are only as good as the experimental data used to train and refine them. Every round of the Lab-in-the-Loop cycle depends on fast, accurate, high-volume binding affinity data to determine which candidates actually work — and that data can only be generated in the wet lab.
Legacy approaches to binding characterization, often limited to simple yes/no assays or low-throughput instruments, are increasingly giving way to platforms built to match the scale of candidate pools that AI models now generate. Carterra (搜索)'s platforms combine proprietary microfluidics with real-time HT-SPR, delivering up to 100 times the throughput of traditional label-free platforms while using a fraction of the sample.
Industry Validation from Key Players
"This report reinforces what we're hearing directly from our customers: as AI generates larger and more complex sets of antibody candidates, the bottleneck shifts to how quickly and accurately those candidates can be validated at the bench," said Josh Eckman, CEO and co-founder of Carterra (搜索). "Carterra's high-throughput SPR platforms were built for exactly this kind of scale, and we believe we're well positioned to benefit as Lab-in-the-Loop becomes the default way biologics programs are run."
Ten of Carterra (搜索)'s customers are named in the Leerink report, and several have already described the shift in scale that the analysis anticipates. Twist Bioscience (搜索), identified by Leerink as the largest structural beneficiary of the Lab-in-the-Loop shift, has pointed to Carterra's role in generating the antibody binding data sets that large-scale AI discovery programs depend on. At the Protein and Antibody Engineering Summit (PEGS Boston) in May 2026, Twist Biopharma Solutions CSO Dr. Colby Souders described the part Carterra's platforms play in its partnership with AWS Biodiscovery to generate binding data at the scale required by modern AI-guided discovery campaigns.
Julian Englert, CEO and co-founder of Adaptyv Bio (搜索), a protein engineering company supporting AI-driven biologics programs also named in the report, offered an even more bullish assessment. "The market opportunity may be understated. AI in drug discovery is here to stay and we believe Leerink's estimate of a ~$4B antibody discovery market may be low," Englert said. "At Adaptyv, we are seeing massive increases in both orders for our protein synthesis but also the size of projects being requested. We have deployed the most sophisticated and high-throughput technologies, like Carterra (搜索) platforms, to maintain our leadership in the space."
Technology Foundation and Market Position
Carterra (搜索) has spent more than two decades developing label-free biosensor technology, with early support from Pfizer, and its systems are used across the majority of the world's largest pharmaceutical companies today for both biologics and small molecule characterization. The company's HT-SPR platforms sit at the intersection of AI-driven computational design and experimental validation, a position the Leerink report suggests will become increasingly central as the Lab-in-the-Loop paradigm reshapes antibody discovery workflows across the pharmaceutical industry.